Historically, such behavioral complexity was viewed as a disqualifying feature for drug development, as CNS-acting agents were associated with unpredictable neuropsychiatric liability and high regulatory barriers ( 5.4 Translational lessons from abandoned appetite peptides The historical trajectory of appetite and behavioral peptides reveals a recurring pattern: early development efforts often failed due to inadequate control over exposure, insufficient combination strategies, or overly conservative interpretations of side effects
In Canada, drug prices are influenced by the Patented Medicine Prices Review Board (PMPRB) and provincial formularies, which creates a different price landscape than in the US
The goal at that stage is not continued weight loss, but appetite regulation that supports weight stability and prevents regain
Therefore, a systematic analysis was performed to evaluate potential effects of selective VDCC blockers 12
Both are dominated by gastrointestinal adverse events nausea, constipation, diarrhea, vomiting that are mostly mild-to-moderate and dose-related